Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Ablynx nv
Ablynx nv
Activities:
Regulatory
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Media
Sanofi completes acquisition of Ablynx
Sanofi has now acquired all outstanding shares, warrants and convertible bonds of Ablynx following the expiration of the Squeeze-out procedure
Research & Development
Sanofi to acquire Ablynx for €3.9 billion
The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on addressing multiple disease targets with single multi-specific molecules
Recruitment
Ablynx appoints Dr Robert Friesen as Chief Scientific Officer
Research & Development
Ablynx announces board changes
Finance
Ablynx appoints General Manager
Pharmaceutical
Ablynx appoints Markus Ewert as CBO
Research & Development
Novel Nanobody to begin clinical development in osteoarthritis
Ablynx to receive €15m milestone payment from Merck
Subscribe now